Skip to main content
Top

Open Access 29-01-2025 | Hereditary Angioedema | Short Communication

Characteristics of Patients with Hereditary Angioedema Who Reduced Lanadelumab Treatment Administration Frequency: A Retrospective Observational Study of US Claims Data

Authors: Nicole Princic, Kristin A. Evans, Chintal H. Shah, Krystal Sing, Salomé Juethner, Bob G. Schultz

Published in: Drugs - Real World Outcomes

Login to get access

Abstract

Background

Lanadelumab is the only long-term prophylaxis indicated for reduced administration frequency in patients with hereditary angioedema who have been well controlled for > 6 months. Understanding the characteristics of patients who reduce administration frequency will help identify populations where frequency modifications may be appropriate.

Objective

We aimed to describe characteristics of patients who did and did not reduce lanadelumab administration frequency to inform real-world dosing regimens, and characteristics indicative of sustained frequency reduction.

Methods

A retrospective observational study using healthcare insurance data in the USA from the Merative™ MarketScan® Commercial and Medicare Databases identified patients persistent on lanadelumab for ≥ 18 months. Reduced administration frequency was defined as a ≥ 25% decrease in lanadelumab costs during months 7–12 or 13–18 versus 0–6. Hereditary angioedema attack triggers/symptoms and hereditary angioedema-related healthcare encounters, treatment, and costs were assessed.

Results

Of 54 identified patients, 25 reduced administration frequency. Two patients returned to initial dosing frequency during months 13–18 after reducing during months 7–12. Patients who reduced administration frequency experienced fewer hereditary angioedema attack triggers/symptoms before lanadelumab initiation (baseline) and during months 0–6 than those who did not; they also had a lower mean number of hereditary angioedema-related inpatient admissions, emergency room visits, and outpatient visits during baseline, had fewer claims for acute treatment (60.0% vs 65.5%) and prior long-term prophylaxis (20.0% vs 27.6%), and had lower mean hereditary angioedema treatment costs at baseline ($139,520 vs $233,815) than those who did not.

Conclusions

This real-world analysis suggests that patients with less frequent hereditary angioedema-related healthcare encounters, lower disease activity, and lower costs within 6 months before lanadelumab initiation are more likely to achieve reduced dosing frequency.
Appendix
Available only for authorised users
Literature
1.
go back to reference Bernstein JA. Severity of hereditary angioedema, prevalence, and diagnostic considerations. Am J Manag Care. 2018;24(14 Suppl.):S292–8.PubMed Bernstein JA. Severity of hereditary angioedema, prevalence, and diagnostic considerations. Am J Manag Care. 2018;24(14 Suppl.):S292–8.PubMed
2.
go back to reference Busse PJ, Christiansen SC, Riedl MA, Banerji A, Bernstein JA, Castaldo AJ, et al. US HAEA Medical Advisory Board 2020 guidelines for the management of hereditary angioedema. J Allergy Clin Immunol Pract. 2021;9(1):132-50.e3.CrossRefPubMed Busse PJ, Christiansen SC, Riedl MA, Banerji A, Bernstein JA, Castaldo AJ, et al. US HAEA Medical Advisory Board 2020 guidelines for the management of hereditary angioedema. J Allergy Clin Immunol Pract. 2021;9(1):132-50.e3.CrossRefPubMed
3.
go back to reference Lumry WR, Settipane RA. Hereditary angioedema: epidemiology and burden of disease. Allergy Asthma Proc. 2020;41(Suppl. 1):S08-13.CrossRefPubMed Lumry WR, Settipane RA. Hereditary angioedema: epidemiology and burden of disease. Allergy Asthma Proc. 2020;41(Suppl. 1):S08-13.CrossRefPubMed
4.
go back to reference Riedl MA, Danese M, Danese S, Ulloa J, Maetzel A, Audhya PK. Hereditary angioedema with normal C1 inhibitor: US survey of prevalence and provider practice patterns. J Allergy Clin Immunol Pract. 2023;11(8):2450-6.e6.CrossRefPubMed Riedl MA, Danese M, Danese S, Ulloa J, Maetzel A, Audhya PK. Hereditary angioedema with normal C1 inhibitor: US survey of prevalence and provider practice patterns. J Allergy Clin Immunol Pract. 2023;11(8):2450-6.e6.CrossRefPubMed
6.
go back to reference Banerji A, Davis KH, Brown TM, Hollis K, Hunter SM, Long J, et al. Patient-reported burden of hereditary angioedema: findings from a patient survey in the United States. Ann Allergy Asthma Immunol. 2020;124(6):600–7.CrossRefPubMed Banerji A, Davis KH, Brown TM, Hollis K, Hunter SM, Long J, et al. Patient-reported burden of hereditary angioedema: findings from a patient survey in the United States. Ann Allergy Asthma Immunol. 2020;124(6):600–7.CrossRefPubMed
7.
go back to reference Longhurst H, Bygum A. The humanistic, societal, and pharmaco-economic burden of angioedema. Clin Rev Allergy Immunol. 2016;51(2):230–9.CrossRefPubMed Longhurst H, Bygum A. The humanistic, societal, and pharmaco-economic burden of angioedema. Clin Rev Allergy Immunol. 2016;51(2):230–9.CrossRefPubMed
8.
go back to reference Lumry WR, Castaldo AJ, Vernon MK, Blaustein MB, Wilson DA, Horn PT. The humanistic burden of hereditary angioedema: impact on health-related quality of life, productivity, and depression. Allergy Asthma Proc. 2010;31(5):407–14.CrossRefPubMed Lumry WR, Castaldo AJ, Vernon MK, Blaustein MB, Wilson DA, Horn PT. The humanistic burden of hereditary angioedema: impact on health-related quality of life, productivity, and depression. Allergy Asthma Proc. 2010;31(5):407–14.CrossRefPubMed
9.
go back to reference Mendivil J, Murphy R, de la Cruz M, Janssen E, Boysen HB, Jain G, et al. Clinical characteristics and burden of illness in patients with hereditary angioedema: findings from a multinational patient survey. Orphanet J Rare Dis. 2021;16(1):94.CrossRefPubMedPubMedCentral Mendivil J, Murphy R, de la Cruz M, Janssen E, Boysen HB, Jain G, et al. Clinical characteristics and burden of illness in patients with hereditary angioedema: findings from a multinational patient survey. Orphanet J Rare Dis. 2021;16(1):94.CrossRefPubMedPubMedCentral
10.
go back to reference Patel G, Pongracic JA. Hereditary and acquired angioedema. Allergy Asthma Proc. 2019;40(6):441–5.CrossRefPubMed Patel G, Pongracic JA. Hereditary and acquired angioedema. Allergy Asthma Proc. 2019;40(6):441–5.CrossRefPubMed
11.
go back to reference Betschel S, Badiou J, Binkley K, Borici-Mazi R, Hébert J, Kanani A, et al. The International/Canadian Hereditary Angioedema guideline. Allergy Asthma Clin Immunol. 2019;15:72.CrossRefPubMedPubMedCentral Betschel S, Badiou J, Binkley K, Borici-Mazi R, Hébert J, Kanani A, et al. The International/Canadian Hereditary Angioedema guideline. Allergy Asthma Clin Immunol. 2019;15:72.CrossRefPubMedPubMedCentral
12.
go back to reference Maurer M, Magerl M, Betschel S, Aberer W, Ansotegui IJ, Aygören-Pürsün E, et al. The International WAO/EAACI guideline for the management of hereditary angioedema: the 2021 revision and update. Allergy. 2022;77(7):1961–90.CrossRefPubMed Maurer M, Magerl M, Betschel S, Aberer W, Ansotegui IJ, Aygören-Pürsün E, et al. The International WAO/EAACI guideline for the management of hereditary angioedema: the 2021 revision and update. Allergy. 2022;77(7):1961–90.CrossRefPubMed
13.
go back to reference Betschel SD, Banerji A, Busse PJ, Cohn DM, Magerl M. Hereditary angioedema: a review of the current and evolving treatment landscape. J Allergy Clin Immunol Pract. 2023;11(8):2315–25.CrossRefPubMed Betschel SD, Banerji A, Busse PJ, Cohn DM, Magerl M. Hereditary angioedema: a review of the current and evolving treatment landscape. J Allergy Clin Immunol Pract. 2023;11(8):2315–25.CrossRefPubMed
14.
go back to reference Fijen LM, Bork K, Cohn DM. Current and prospective targets of pharmacologic treatment of hereditary angioedema types 1 and 2. Clin Rev Allergy Immunol. 2021;61(1):66–76.CrossRefPubMedPubMedCentral Fijen LM, Bork K, Cohn DM. Current and prospective targets of pharmacologic treatment of hereditary angioedema types 1 and 2. Clin Rev Allergy Immunol. 2021;61(1):66–76.CrossRefPubMedPubMedCentral
15.
go back to reference Mendivil J, DerSarkissian M, Banerji A, Diwakar L, Katelaris CH, Keith PK, et al. A multicenter chart review of patient characteristics, treatment, and outcomes in hereditary angioedema: unmet need for more effective long-term prophylaxis. Allergy Asthma Clin Immunol. 2023;19(1):48.CrossRefPubMedPubMedCentral Mendivil J, DerSarkissian M, Banerji A, Diwakar L, Katelaris CH, Keith PK, et al. A multicenter chart review of patient characteristics, treatment, and outcomes in hereditary angioedema: unmet need for more effective long-term prophylaxis. Allergy Asthma Clin Immunol. 2023;19(1):48.CrossRefPubMedPubMedCentral
19.
go back to reference Shah CH, Princic N, Evans KA, Schultz BG. Real-world changes in costs over time among patients in the United States with hereditary angioedema on long-term prophylaxis with lanadelumab. J Med Econ. 2023;26(1):871–7.CrossRefPubMed Shah CH, Princic N, Evans KA, Schultz BG. Real-world changes in costs over time among patients in the United States with hereditary angioedema on long-term prophylaxis with lanadelumab. J Med Econ. 2023;26(1):871–7.CrossRefPubMed
20.
go back to reference Sexton D, Nguyen HQ, Juethner S, Luo H, Zhang Z, Jasper P, et al. A quantitative systems pharmacology model of plasma kallikrein-kinin system dysregulation in hereditary angioedema. J Pharmacokinet Pharmacodyn. 2024;51(6):721–34.CrossRefPubMedPubMedCentral Sexton D, Nguyen HQ, Juethner S, Luo H, Zhang Z, Jasper P, et al. A quantitative systems pharmacology model of plasma kallikrein-kinin system dysregulation in hereditary angioedema. J Pharmacokinet Pharmacodyn. 2024;51(6):721–34.CrossRefPubMedPubMedCentral
Metadata
Title
Characteristics of Patients with Hereditary Angioedema Who Reduced Lanadelumab Treatment Administration Frequency: A Retrospective Observational Study of US Claims Data
Authors
Nicole Princic
Kristin A. Evans
Chintal H. Shah
Krystal Sing
Salomé Juethner
Bob G. Schultz
Publication date
29-01-2025
Publisher
Springer International Publishing
Published in
Drugs - Real World Outcomes
Print ISSN: 2199-1154
Electronic ISSN: 2198-9788
DOI
https://doi.org/10.1007/s40801-024-00470-x